<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006086</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068078</org_study_id>
    <secondary_id>MCC-12176</secondary_id>
    <secondary_id>BMS-CA159-003</secondary_id>
    <secondary_id>NCI-G00-1825</secondary_id>
    <nct_id>NCT00006086</nct_id>
  </id_info>
  <brief_title>BMS-188797 and Carboplatin in Treating Patients With Advanced Nonhematologic Cancer</brief_title>
  <official_title>Phase I Study of BMS-188797 in Combination With Carboplatin in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of BMS-188797 and carboplatin in treating&#xD;
      patients who have advanced nonhematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the recommended phase II dose based on the maximum tolerated dose of&#xD;
           BMS-188797 when administered with carboplatin in patients with advanced nonhematologic&#xD;
           malignancies.&#xD;
&#xD;
        -  Assess the dose limiting toxicities and safety of this treatment regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine any antitumor activity of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of BMS-188797.&#xD;
&#xD;
      Patients receive BMS-188797 IV over 1 hour followed by carboplatin IV over 30 minutes on day&#xD;
      1. Treatment repeats every 21 days for a minimum of 2 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BMS-188797 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6&#xD;
      patients experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed for 4 weeks, and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-188797</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced nonhematologic malignancy that has&#xD;
             progressed on standard therapy or for which no curative therapy exists&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST no greater than 2.5 times upper limit of normal (ULN) unless due to&#xD;
             hepatic metastases&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No chronic medical condition requiring treatment with corticosteroids&#xD;
&#xD;
          -  No prior severe hypersensitivity reaction to agents containing Cremophor&#xD;
             (polyoxyethylated castor oil)&#xD;
&#xD;
          -  No serious uncontrolled medical disorder, active infection, or psychiatric disorder&#xD;
             (e.g., dementia) that would preclude study&#xD;
&#xD;
          -  No preexisting neurotoxicity grade 1 or greater&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  No prior platinum or taxane therapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy (except megestrol for anorexia/cachexia)&#xD;
             and recovered&#xD;
&#xD;
          -  At least 7 days since prior corticosteroids&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy to 30% or more of bone marrow and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Sullivan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan 15;12(2):523-8. doi: 10.1158/1078-0432.CCR-05-0928.</citation>
    <PMID>16428495</PMID>
  </results_reference>
  <verification_date>September 2002</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>May 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2003</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

